Nov 5, 2026, 13:07
Five-Year Outcomes of Hemophilia Gene Therapy – Global Hemophilia Report
Global Hemophilia Report shared a post on LinkedIn:
“Five years after gene therapy, what does sustained factor expression mean for patients with hemophilia?
On the latest Global Hemophilia Report, Dr. Steven Pipe discusses five-year outcomes, including patients managing trauma and undergoing surgery without additional factor replacement.
Listen in for key insights on assessing the durability of gene therapy outcomes.
Guests:
- Steven Pipe, MD – Hematologist, Professor of Pediatrics and Pathology, University of Michigan
- Len Valentino, MD – President, World Federation of Hemophilia USA
- Kenneth Friedman, MD – Senior Medical Director, Hematology, Versiti Blood Center of Wisconsin
Hosted by: Patrick James Lynch.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Nov 5, 2026, 13:42Hélène Gleitz-Broeders: How MPNs Reshape the Bone Marrow Microenvironment
-
Nov 5, 2026, 13:40Augustina Isioma Ikusemoro: The Role of Blood Conservation in PBM
-
Nov 5, 2026, 13:36Vera Ignjatović: Paediatric Thrombosis and Haemostasis Takes Centre Stage in Serbia
-
Nov 5, 2026, 13:31Mahinour Oraby: Hemophilia Awareness – The First Step Toward Better Care
-
Nov 5, 2026, 13:25Mukhtar Buhlaiga: Advancing Laboratory and Transfusion Medicine Through Innovation
-
Nov 5, 2026, 13:22Duane Day: A Novel Assay for Measuring Active Factor XIa
-
Nov 5, 2026, 13:20Bruno Pougault։ D-Dimer in Infection and Suspected VTE
-
Nov 5, 2026, 12:59Marius Tanase։ Building Stronger Partnerships for Better Bleeding Disorders Care
-
Nov 5, 2026, 12:43George Giannakoulas: NLR as a Predictor of Outcomes in Acute Coronary Syndromes